Study record
Lifestyle change and telomere length: 5-year follow-up (Ornish et al., 2013)
Human pilot — telomere-length biomarker (5-year)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 4 — Human pilot / observational — biomarker
Record
| Design | Descriptive pilot, 5-year follow-up (telomere-length biomarker; non-randomized comparison) |
| N | 35 |
| DOI | 10.1016/S1470-2045(13)70366-8 |
| Citation status | doi verified via Crossref 2026-07-12 (Lancet Oncol 2013;14(11):1112-1120, Ornish et al., 'Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study'). PMID not separately fetched (DOI is the confirmed primary identifier). |
Five-qualifier claim
| Species / population | Men with biopsy-proven low-risk prostate cancer (5-year follow-up of the pilot; intervention vs comparison group, ~35 total). |
| Exposure, route, schedule | Comprehensive lifestyle change maintained over 5 years. |
| Comparator / duration | Non-randomized comparison group (active surveillance); 5-year follow-up of the descriptive pilot. |
| Endpoint / numeric result | Relative telomere length increased in the lifestyle group and decreased in controls over 5 years; however, the earlier telomerase-activity increase was not sustained. |
| What it did NOT establish | A small, non-randomized descriptive pilot with a contested biomarker (telomere length). It does not establish a healthy-aging, clinical-outcome, or lifespan benefit. |
Interventions
Primary reference
https://doi.org/10.1016/S1470-2045(13)70366-8
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.